Genticel, a French biopharmaceutical company that develops vaccines for patients infected with the human papillomavirus (HPV), has appointed a new Vice-President to its supervisory board.
Dr Gerald Moeller, has over 35 years' experience in the pharmaceutical and diagnostics industry. He has been an investment adviser at HBM Partners in Switzerland since 2002 and chairs the supervisory boards of a number of health sector companies, including 4Sigma, Definiens, Invendo-Medical and MorphoSys. He is also a board member with FIND Foundation and Illumina.
'We are very pleased that Dr Moeller is joining our supervisory board,' said Benedikt Timmerman, founder and CEO of Genticel. 'His wealth of expertise in the pharmaceutical industry represents a considerable asset for Genticel, especially at a key moment in our development. We are launching the Phase II clinical trial of our lead product, ProCervix, in Europe – so it is a priority for Genticel to forge close ties with major pharmaceutical industry players. Gerry's experience in this industry and his strategic advice will be invaluable in this.'
Dr Moeller is a former CEO of the Boehringer Mannheim Group and Director of international development and strategic marketing for the pharmaceutical division. He was also a member of Roche's executive committee.
In the biotechnology sector, Dr Moeller is a member of the board of Bionostics, Brahms, MTM Laboratories, PowderJect Pharmaceuticals, Strakan, Vivacta and Sugen.
